Drug Design of GLP-1 Receptor Agonists: Importance of In Silico Methods

Smriti Sharma; Vinayak Bhatia

doi:10.2174/1381612826666201118094502

Drug Design of GLP-1 Receptor Agonists: Importance of In Silico Methods

Curr Pharm Des. 2021;27(8):1015-1024. doi: 10.2174/1381612826666201118094502.

Authors

Smriti Sharma¹, Vinayak Bhatia²

Affiliations

¹ Department of Chemistry, Miranda House, University of Delhi, Delhi, India.
² ICARE Eye Hospital and Postgraduate Institute, U.P., Noida, India.

PMID: 33213316
DOI: 10.2174/1381612826666201118094502

Abstract

Drug design based on degradation-resistant, long-acting Glucagon-like peptide-1 receptor (GLP-1R) agonists for treating type 2 diabetes is attracting a lot of attention. Here, the authors have examined in detail how in silico drug design is aiding in developing novel GLP-1 receptor agonist drugs. Their pharmacotherapy and adverse effects have also been summarized. After the analysis of currently available information on this topic, the authors feel that in silico method is a great auxiliary tool in almost all the experimental studies on GLP-1 receptors and is highly efficient in identifying novel drug molecules that can act as GLP-1 receptor agonists.

Keywords: CADDD; GLP-1; GLP-1 receptor agonists; In Silico; Type 2 diabetes mellitus (T2DM); drug design; molecular docking.

MeSH terms

Computer Simulation
Diabetes Mellitus, Type 2* / drug therapy
Drug Design
Glucagon-Like Peptide-1 Receptor
Humans
Hypoglycemic Agents / pharmacology
Pharmaceutical Preparations*

Substances

Glucagon-Like Peptide-1 Receptor
Hypoglycemic Agents
Pharmaceutical Preparations